This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignee: Wilex Ag. Active years: 2011.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2011
Title: Francesco Blasi: Innovator in Monoclonal Antibodies
Introduction
Francesco Blasi is a notable inventor based in Segrate, Italy. He has made significant contributions to the field of biotechnology, particularly in the development of monoclonal antibodies. His work focuses on innovative solutions that address critical medical challenges.
Latest Patents
Francesco Blasi holds a patent for "Monoclonal antibodies specific for the chemotactic epitope of the urokinase-type plasminogen activator receptor." This invention describes monoclonal antibodies that specifically target the chemotactic epitope of the urokinase-type plasminogen activator receptor (uPAR). The patent details antibodies that recognize fragments of uPAR, particularly the chemotactic sequence connecting domain 1 to domain 2. He has 1 patent to his name.
Career Highlights
Francesco Blasi is associated with Wilex AG, a company known for its focus on developing innovative cancer therapies. His work at Wilex AG has positioned him as a key player in the biotechnology sector, contributing to advancements in therapeutic solutions.
Collaborations
Francesco has collaborated with notable professionals in his field, including Massimo Resnati and Nicolai Sidenius. These collaborations have enhanced the research and development efforts in monoclonal antibody technology.
Conclusion
Francesco Blasi's contributions to the field of monoclonal antibodies exemplify his commitment to innovation in biotechnology. His patent and work at Wilex AG highlight his role as a significant inventor in this vital area of research.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile